Expression of the SART-1 tumor rejection antigen in Breast

我们研究了编码肿瘤排斥抗原的SART-1基因在乳腺癌中的表达。所有受试样本均表达SART-1mRNA。在50例乳腺癌组织中有20例(40%)和所有乳腺癌细胞系中检测到SART-L抗原，而在正常乳腺组织中未检测到该抗原。转染了人类白细胞抗原A2601和人类白细胞抗原A2402基因的SART-1乳腺癌细胞可分别被人类白细胞抗原A26限制性和SART-1特异性细胞毒性T淋巴细胞或人类白细胞抗原A24限制性和SART-1特异性CTL识别。在20例SART-1肿瘤中，9例表达雌激素受体，8例表达孕激素受体。因此，单倍型为-A26或-A24的患者可能适合单独使用SART-1多肽或联合激素治疗进行特异性免疫治疗。

We investigated in breast cancers the expression of the SART-1 gene encoding tumor rejection antigens. SART-1 mRNA was expressed in all of the samples tested. The SART-l antigen was detectable in 20 of 50 (40%) breast cancer tissues and all breast cancer cell line tested, but not in normal breast tissues. The SART-1 breast cancer cells transfected with HLA-A2601 or HLA-A2402 cDNA were recognized by the HLA-A26-restricted and SART-1 specific cytotoxic T lymphocytes (CTLs) or the HLA-A24-restricted and SART-1-speciflC CTLs, respectively. Among the 20 SART-1 tumors, 9 or 8 tumors expressed estrogen receptor or progesterone receptor, respectively. Therefore, the patients with HLA-A26 or -A24 haplotype might be appropriate candidates for specific immunotherapy with the SART-1 peptides independently or in combination with hormone therapy.